| Variable |
n (%) |
| Sex |
|
| Boys |
31 (50.8) |
| Girls |
30 (49.2) |
| Age (years) |
|
| 0–3 years |
23 (37.7) |
| 4–10 years |
21 (34.4) |
| > 11 years |
17 (27.9) |
| Race |
|
| Caucasian |
48 (78.7) |
| Asian |
1 (1.6) |
| Black |
4 (6.6) |
| Other |
8 (13.1) |
| Sillence type |
|
| I |
31 (50.8) |
| III |
14 (23.0) |
| IV |
16 (26.2) |
| BMIℓ |
|
| Low (< 5%) |
7 (17.1) |
| Normal (5%–95%) |
27 (65.9) |
| High (> 95%) |
7 (17.1) |
| Vitamin D level |
|
| Deficient (< 20 ng/ml) |
9 (14.8) |
| Insufficient (20–32 ng/ml) |
22 (36.1) |
| Sufficient (> 32 ng/ml) |
30 (49.1) |
| Calcium serum level† |
|
| Normal |
38 (97.4) |
| High |
1 (2.6) |
| Phosphorus serum level‡ |
|
| Normal |
33 (91.7) |
| High |
3 (8.3) |
| Pamidronate treatment |
|
| With treatment |
38 (62.3) |
| Without treatment |
23 (37.7) |
| Fracture (during study period) |
|
| Less than 10 |
29 (47.5) |
| More than 10 |
32 (52.5) |
Notes and abbreviation: n = number of patients. ℓBody mass index (BMI): 5 patients with missing height/length data and 15 patients were younger than two years. †Twenty-two patients with no calcium serum level evaluation done with vitamin D level evaluation. ‡Twenty-five patients with no phosphorus serum level evaluation done with vitamin D level evaluation. |